Sweden · Delayed Price · Currency is SEK Teneo AI AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw a sharp revenue and ARR decline due to a partner dispute, but gross margins remained strong and the sales pipeline is at record levels. Strategic review and patent enforcement are underway, with new deals expected to drive future growth.
Fiscal Year 2025
-
Q4 2025 saw a sharp revenue and ARR decline due to a partner dispute, but a strong pipeline, new product launches, and secured financing position the company for recovery. Patent strength and industry-specific solutions drive competitive differentiation.
-
SaaS revenues and API call volumes grew strongly year-over-year, with a stable 87% gross margin and 121% NRR. The launch of Teneo 8 and a robust pipeline support the $20M ARR target by end of Q1, despite currency headwinds and timing uncertainties.
-
Strong year-over-year growth driven by SaaS and high gross margins, with a robust pipeline and industry validation as the top conversational AI vendor. U.S. expansion is on track, and the company targets $20M ARR by Q1, despite currency and seasonal headwinds.
-
SaaS API call revenues grew 185% year-over-year, with SaaS ARR up 101% and gross margin stable at 86%. A robust U.S.-focused pipeline and new sales hires support the SEK 200 million ARR target, with revenue acceleration expected after summer.
Fiscal Year 2024
-
Q4 2024 saw record SaaS growth, 135% NRR, and first cash flow positive month, driven by large US enterprise focus and a breakthrough partnership with Genesys. Gross margin rose to 87%, ARR surpassed SEK 104 million, and cash position was strengthened for 2025 expansion.
-
Record quarter with 90% year-over-year revenue growth, driven by SaaS API call expansion and strong gross margins. Most SaaS customers are growing, with new features accelerating multilingual deployments and automation. Cash position remains solid, and the company is confident in meeting future growth targets.
-
Rebranding to Teneo AI, the company delivered record Q2 growth with recurring revenues up 31% and SaaS ARR up 47% year-over-year. Strong technology innovation, new healthcare wins, and a robust cash position support aggressive U.S. and U.K. expansion.